Patent cliff

From Wikipedia, the free encyclopedia
Jump to: navigation, search

The term patent cliff refers to the phenomenon of patent expiration dates and an abrupt drop in sales that follows for a group of products capturing high percentage of a market. Usually, these phenomena are noticed when they affect blockbuster products—a blockbuster product in the pharmaceutical industry, for example, is defined as a product with sales exceeding 1 billion USD per year.[1][2]

The abrupt drop in sales expected after the date of patent expiration can be estimated with the following formula:[2]

where A is the peak sales value before the patent expiration and Y the years after the peak sales year (the peak sales year is considered year 0), and B is an exponent with value -1.032. The formula above could be simplified for practical calculations to:

Pharmaceutical industry[edit]

For example, Plavix, Singulair, Diovan and Lipitor are all chemical blockbuster drugs discovered in the early 1990s, with patent expiration date falling between 2011 and 2015; and Rituxan, Humira, Novolog and Avastin are biologic blockbuster drugs discovered in the late 1990s, with patent expiration date between 2014 and 2019.[2] Thus, the revenue obtained through the sales of these products is at risk of falling drastically within the years of the patent cliff, which is often seen as an opportunity for other companies to generate revenue from selling generic or similar products.

Pharmaceutical companies expend significant resources in seeking routes to patent extensions. For instance, one method is to develop a new delivery method for the therapeutic.[3]

See also[edit]

References[edit]

  1. ^ DG Competition Staff (28 November 2008). Pharmaceutical Sector Inquiry: Preliminary Report (PDF) (Report). European Commission. 
  2. ^ a b c Calo-Fernández, Bruno; Martínez-Hurtado, Juan Leonardo (2012). "Biosimilars: Company Strategies to Capture Value from the Biologics Market". Pharmaceuticals. 5 (12): 1393–1408. doi:10.3390/ph5121393. PMC 3816668Freely accessible. PMID 24281342. 
  3. ^ Wright, Rob (5 February 2018). "Is It Time For Branded Biopharmaceuticals To Get Into The Business Of Generics?". Life Science Leader (Blog). VertMarkets. Retrieved 15 February 2018. 

Further reading[edit]

  • Calo-Fernández, B.; Martínez-Hurtado, J.L. Biosimilars: Company Strategies to Capture Value from the Biologics Market. Pharmaceuticals 2012, 5, 1393-1408. Available at: (http://www.mdpi.com/1424-8247/5/12/1393/pdf)